SNT Biotech in the News:

SNT Biotech Announces Strategic Partnership with Waters Corporation to Expand Access to FDA-Cleared At-Home HPV Screening

June 26, 2026

SNT Biotech today announced a strategic partnership with Waters Corporation to expand access to one of the most comprehensive FDA-cleared at-home HPV screening solutions for cervical cancer available in the United States.

The partnership supports SNT Biotech's mission to improve access to preventive care through scalable population health programs, with a particular focus on Medicaid, ACA Marketplace, rural, and other underserved populations where barriers to screening remain significant.

Nearly 25 million women in the United States are behind on cervical cancer screening or have never been screened. Many face challenges such as transportation, work schedules, childcare responsibilities, language barriers, or limited access to healthcare services. Expanding access to at-home screening has the potential to help more women participate in recommended preventive care.

SNT Biotech works with health plans, health systems, provider organizations, employers, and community organizations to support population health initiatives that improve access to preventive screening and help close gaps in care.

"This partnership represents an important milestone for our company and our mission," said Shital Daftari, Founder and CEO of SNT Biotech. "From the beginning, our goal has been to build a company with scale and purpose, one that helps expand access to preventive care and ultimately saves lives through early detection."

The Onclarity™ HPV Self-Collection Kit is tested with the BD Onclarity™ HPV Assay, which detects 14 high-risk HPV genotypes and is the only FDA-approved HPV assay that individually identifies six high-risk HPV genotypes while strategically grouping three additional results, making it one of the most comprehensive HPV screening solutions available in the United States today.

The full announcement is available on PR Newswire.

About SNT Biotech

SNT Biotech is a national population health company that partners with health plans, health systems, employers, and community organizations to improve access to preventive care. The company provides end-to-end screening programs across cervical cancer screening, colorectal cancer screening, diabetes management, and kidney health, combining laboratory services, technology, logistics, and member engagement to help organizations reach populations that have historically faced barriers to care.

Regulatory Disclaimer

The BD Biosciences and BD Diagnostic Solutions businesses have been acquired by Waters Corporation ("Waters"). Becton, Dickinson and Company or one of its affiliates or subsidiaries ("BD") remains the legal manufacturer of Biosciences and Diagnostic Solutions products until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under BD's regulatory authority. For additional information, please visit https://www.waters.com/bdtransaction.

The Onclarity™ HPV Self-Collection Kit, tested with the BD Onclarity™ HPV Assay, is the most comprehensive at-home cervical cancer screening tool available in the U.S. today. Credit: Waters Corp.